Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

705
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
705
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

274
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
274

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipid Composition Drives Mutant Huntingtin Dimerization and Membrane Association: Insights from Computational Simulations.

Molecules (Basel, Switzerland)·2026
Same author

Targeting GPR18: Structural modelling, ligand discovery, and therapeutic potential in neuroinflammatory disorders.

Biochemical pharmacology·2026
Same author

Sustained Palmitoylethanolamide Infusion Restores Incentive Motivation and Synaptic Plasticity in the Tg2576 Mouse Model of Alzheimer's Disease.

Cells·2026
Same author

Unraveling Endocannabinoid Signaling Pathways in Cisplatin-Induced Ototoxicity.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same author

Specialized pro-resolving mediators and autoimmunity: Recent insights and future perspectives.

Autoimmunity reviews·2025
Same author

Genetic characterization of the endocannabinoid system and psychiatric features in patients with migraine and medication overuse headache.

Cephalalgia : an international journal of headache·2025

Related Experiment Video

Updated: Sep 27, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.0K

Microglial Endocannabinoid Signalling in AD.

Lucia Scipioni1,2, Francesca Ciaramellano2,3, Veronica Carnicelli1

  • 1Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio Snc, 67100 L'Aquila, Italy.

Cells
|April 12, 2022
PubMed
Summary

Endocannabinoids (eCBs) modulate brain immune cell activity in Alzheimer's disease (AD). This review explores how eCB signaling impacts microglial phenotypes and function during neurodegeneration and homeostasis.

Keywords:
Alzheimer’s diseaseendocannabinoidmicroglianeuroinflammation

More Related Videos

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
04:22

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Published on: May 20, 2024

1.0K
Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
10:46

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

11.4K

Related Experiment Videos

Last Updated: Sep 27, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.0K
Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
04:22

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Published on: May 20, 2024

1.0K
Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
10:46

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

11.4K

Area of Science:

  • Neuroimmunology
  • Neuropharmacology
  • Alzheimer's Disease Research

Background:

  • Chronic inflammation is a key driver of Alzheimer's disease (AD) pathogenesis.
  • Microglial cells, the brain's immune cells, play a critical role in AD by performing functions like phagocytosis and releasing inflammatory mediators.
  • The effects of microglial activity can vary depending on the disease stage and specific cell phenotype.

Purpose of the Study:

  • To review the current literature on the role of the endocannabinoid (eCB) system in modulating microglial activity.
  • To understand how eCB signaling influences microglial phenotypes in both healthy and AD-affected brains.
  • To explore the impact of eCBs on neurodegeneration and brain homeostasis.

Main Methods:

  • Literature review of scientific publications.
  • Analysis of studies investigating endocannabinoid signaling pathways.
  • Examination of research on microglial function in Alzheimer's disease models and human studies.

Main Results:

  • Endocannabinoids (eCBs) are increasingly recognized for their crucial role in regulating microglial cell activity.
  • The eCB system can influence microglial phenotypes, impacting their pro-inflammatory or anti-inflammatory actions.
  • Evidence suggests eCB signaling is involved in both normal brain function and the pathological processes of AD.

Conclusions:

  • The endocannabinoid system is a significant modulator of microglial behavior in the context of Alzheimer's disease.
  • Targeting the eCB system may offer therapeutic strategies for managing neuroinflammation and neurodegeneration in AD.
  • Further research into eCB signaling is essential for understanding and treating AD.